After the end of the second world war, the world saw a significant period of growth and prosperity unlike any previously. By the 1950s, morbid obesity was proving to be a clinical problem in many developed societies in Europe and North America. Diet, lifestyle and medication alone did not appear to be effective in controlling morbid obesity, and surgical interventions were developed. Surgical therapies to combat the epidemic of obesity evolved from intestinal bypasses (which had the potential for serious fluid, electrolyte and nutritional disturbances) to eventually settle on manipulations that involve restrictive procedures of the stomach with or without bypass of the duodenum and jejunum. This branch of surgery was referred to as "bariatric" (from the Greek "baros" for weight), but recent awareness that concomitant obesity-related metabolic diseases can also be effectively treated by these procedures has given rise to the new specialty of metabolic-bariatric surgery (MBS). This review looks at current MBS procedures and their impact on gastro-intestinal physiology to achieve both weight loss and metabolic control.
INtrODUctION
Obesity is often regarded as a cosmetic problem by the public at large. However, from a medical standpoint, obesity has important clinical implications, especially with regard to the development of metabolic diseases. Although the exact timing of when and in whom obesity should be treated is still controversial, there are well established diagnostic algorithms which may be used to identify individuals who are at greater susceptibility for future morbidity and mortality. For example, the metabolic syndrome (MetS) is defined as a cluster of cardiovascular risk factors of which central (visceral) obesity is the hallmark feature 1 . Other features of the syndrome -glucose intolerance, dyslipidaemia and a raised blood pressure -are all established strong predictors of cardiovascular disease 2, 3 . The MetS therefore identifies the individual bearing a much increased cardiovascular risk, with up to a three-fold increased risk of cardiovascular events and double the risk of cardiovascular mortality compared with individuals without the metabolic syndrome 4 .
With the rise in obesity prevalence worldwide, it is not surprising that the incidence of obesity-related conditions, in particular type 2 diabetes mellitus, has synchronously risen sharply 5, 6 . In Singapore, the rise in obesity prevalence from 6.9% in 2004 to 10.8% in 2010 was paralleled by a significant 40% increase in the prevalence of T2DM (8.2% to 11.3%) 7 .
Fortunately, intensive lifestyle intervention with successful weight loss can markedly improve glycaemic and lipid profiles and cardiovascular risk in diabetic patients 8 . Weight loss can even prevent or delay the development of T2DM in susceptible individuals 9 . However, even within the rigorous setting of a clinical study, most obese individuals struggle to maintain the weight lost 8 .
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Proceedings of Singapore Healthcare  Volume 21  Number 3 2012 Metabolic surgery was defined by Henry Buchwald as "the operative manipulation of a normal organ or organ system to achieve a biological result for potential health gain" 10 . Recent randomised clinical trials confirm the stunning reversal of metabolic disorders noted after bariatric (weight-loss) surgery [11] [12] [13] . Indeed, the improvement in conditions such as type 2 diabetes mellitus, hypertension, dyslipidaemia and non-alcoholic fatty liver disease are so dramatic that they have added a new dimension to bariatric surgery which hitherto was focused on weight loss, giving rise to the emerging specialty of metabolic-bariatric surgery (MBS). In addition, the weight loss and the consequent metabolic benefits are significantly sustainable. The long-term Swedish Obese Subjects study reported average absolute weight loss of 14-25% at 10 years follow-up 14 . Further evidence from the bariatric surgery literature gave rise to the awareness in that weight loss surgery was in fact more significant in treating the concomitant metabolic disorders than obesity itself! MBS is growing at an exponential rate, partly due to the widespread adoption of newer, minimally-invasive (laparoscopic or key-hole) surgical techniques and the use of less aggressive interventions such as gastric banding, which avoid any cutting or stapling of the stomach. In this paper, we will review current metabolic-bariatric procedures and discuss the mechanisms by which they alter gastrointestinal (GI) physiology.
tYPES OF INtErVENtIONS
The surgical options may be divided into two categories according to their mechanism of action: a) restrictive and b) bypass-type ( malabsorptive) procedures.
Restrictive procedures reduce a patient's ability to eat and therefore limit caloric intake. They are gradually gaining traction among both patients and surgeons as they are less complex than the bypasstype procedures, and are less likely to require lifelong vitamin and nutrient supplementation.
Laparoscopic adjustable gastric banding (LAGB) ( fig.  1 ) involves the placement of an inflatable balloon around the proximal circumference of the stomach resulting in a gastric pouch of approximately 15ml 11 . Although the entire stomach is left in-situ, LAGB creates a restriction of the gastric inlet hence forcing patients to eat small morsels and take more time between each mouthful. Video-fluoroscopy studies have shown that each food bolus passes through the supra-band gastric pouch within one to two minutes. Soft and semi-solid foods are well-tolerated but firm and hard foods may get "stuck" or cause reflux symptoms 15 . Patients report an increase in the sensation of satiety, although intolerance to certain (hard) foods is a common complaint 16 .
Laparoscopic sleeve gastrectomy (LSG) ( fig. 2 ) involves the reduction of stomach volume to approximately 15-25% of its original capacity by resection of the fundus and body 17 . A bougie (size range 32-40F) is placed along the lesser curve to guide the resection. This procedure results in a smaller gastric capacity. The antrum is usually retained, although recent reports suggest that more aggressive gastric resection over a smaller bougie may be necessary to prevent weight regain in the long-term 18 . Removal of the fundus results in low levels of the hunger hormone ghrelin which is believed to be an important mechanism by which LSG reduces a patient's appetite and desire to eat 19 . Gastric emptying is enhanced after LSG (presumably because the reduced gastric capacity makes it empty faster) and this leads to early stimulation of incretin hormones such as glucagon-like peptide-1 (GLP-1) and peptide-YY (PYY) 19 .
The most commonly performed bypass-type operation today is the laparoscopic Roux-en-Y gastric bypass (LRYGB) ( fig. 3 ). This is a combined restrictive-malabsorptive procedure which essentially works by (a) reducing the functional stomach to approximately 30ml or less; (b) delaying gastric emptying by reducing the gastric outlet to approximately 12mm or less; and, (c) bypassing the foregut with a 75-150 cm Rouxen-Y gastrojejunostomy, causing reduced nutrient absorption 10 . Depending on the length of the bypassed intestine, there is a risk for malnutrition, in particular of vitamin B12, iron, calcium, and 25-OH vitamin D. Therefore, patients require lifelong vitamin and mineral supplementation. More extensive bypass-type procedures include bilio-pancreatic diversion (BPD) and BPD with duodenal switch (BPD-DS), which result in the largest amount of weight loss, but are associated with higher operative mortality and risk of nutritional deficiencies due to the longer length of intestine bypassed 20 .
Weight loss is greater with the bypasses compared with the restrictive procedures. It is greatest typically at one to two years and mostly sustained at 10-15 years. Unlike medical therapy, weight loss with MBS is durable.
MEtABOLIc EFFEctS
The manipulation of the GI tract in metabolic surgery aims to effect physiologic changes to either improve or "reverse" the various components of the metabolic syndrome, thereby reducing the risk of cardiovascular complications long-term 21 .
With durable weight loss and permanent changes to gastrointestinal anatomy, the beneficial effects of metabolic surgery on the various cardiovascular risks are noted to be sustained as well.
The greatest metabolic risk associated with obesity is T2DM, a progressive disorder characterised by insulin resistance, which is largely as a result of visceral obesity, and concomitant impaired insulin secretion. A large body of evidence suggests that MBS results in remission of T2DM, defined as normal sugars without the use of DM medications, the degree of which is proportional to the extent of excess weight loss, with LAGB having the least (56.7%) and LRYGB and BPD/DS seeing the highest rates of remission (80.3% and 95.1%, respectively) [10] [11] [12] [13] . This remission is sustained in about half of these patients for up to 10 years while matched obese controls on medical weight loss treatment are at a four-fold higher risk of developing diabetes 14 . The benefits of IGT reversal to normoglycaemia after MBS (~99% of subjects) are also noted to be sustained over the 14-year period of the study by Pories et al 22 .
Multiple mechanisms are responsible for this phenomenon, including restriction of caloric intake with resultant weight loss. However, early remission of DM has been reported even before significant weight loss has taken place, triggering postulated mechanisms that MBS invokes altered foregut and hindgut hormonal balances independent of weight loss.
Proponents of gastric bypass are convinced that bypass of the duodenum has a positive impact on glucose metabolism by diminishing inhibitory peptides from the duodenum ("anti-incretins") which oppose the effects of incretin hormones such as glucagon-like peptide 1 (GLP-1) this is called the "foregut hypothesis". After bypass procedures, the increased transit time of food passage leads to rapid delivery of nutrients to the hindgut with accelerated/early and enhanced secretion of GLP-1, which is increased by 40% (the "hindgut hypothesis") 23 .
MOrtALItY OUtcOMES
Despite the higher risks morbidly obese patients pose during surgery, the mortality rates related to MBS are reportedly low at 0.1-2.0%, with greater risks with the more drastic bypass procedures. Common causes of death are pulmonary embolism and anastomotic leaks. In the long-term, MBS has been shown to reduce mortality. In the landmark Swedish Obese Subjects (SOS) study, a wellmatched, prospective study which followed 2010 obese subjects who have undergone MBS and their 2037 matched controls treated medically over 16 years, there was an overall relative reduction in mortality of 34% in MBS subjects, with most of the reduction in cardiovascular and cancer-related deaths 24 .
INDIcAtIONS FOr MEtABOLIc SUrGErY
There is no doubt that MBS benefits morbidly obese patients with multiple features of the metabolic syndrome in the long-term with mortality reductions. For patients suffering from T2DM, the sustained effect of MBS on glycaemic control is so dramatic that the International Diabetes Federation has suggested that MBS may be considered a treatment option in carefully selected patients with a BMI>30kg/m 2 and in whom glycaemic control is sub-optimal despite currently available pharmacotherapy. The Singapore Ministry of Health's 2004 Clinical Practice Guidelines on obesity allows for MBS at a BMI of >32.5kg/m 2 in people with obesity-related conditions like T2DM, dyslipidaemia, OSA and hypertension.
cONcLUSIONS
MBS is a life-changing procedure associated with known risks and complications. Patients should be well informed about the restriction on eating ability and must be prepared to commit to lifelong follow-up to treat and prevent potential complications such as nutrient deficiencies. Generally, there are relatively few contraindications for MBS (eg. unstable coronary artery disease, active cancer with limited life expectancy). However, often overlooked are psychosocial factors such as low socioeconomic status, limited social support, unrealistic expectations and disordered eating habits (eg. binge eating), which are associated with a sub-optimal outcome and should be carefully screened for and dealt with along with the medical and surgical aspects of MBS.
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